EMA Adopts a Positive Opinion for Biosimilar Denosumab By Ogkologos - May 28, 2025 541 0 Facebook Twitter Google+ Pinterest WhatsApp Jubereq is a biosimilar of Xgeva, which was authorised in the EU in 2011 Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR First-Line Pembrolizumab Continues to Show Durable Clinical Benefit After 5 Years... October 31, 2022 NHL Team Surprises Big Fan Who Spent Breast Cancer Treatment Performing... January 22, 2021 Elliot Colburn MP: Why Cancer Research UK’s Manifesto for Cancer Research... May 9, 2023 ESMO Calls for Concerted Action to Prevent Burnout and Foster Well-Being... September 10, 2024 Load more HOT NEWS Coping With Life After a Bone Marrow Transplant: A Survivor’s Story New Study Says At-Home Cancer Care May Lead to Fewer Hospitalizations... Fruquintinib Prolongs Survival Compared with Placebo in Heavily Pretreated Patients with... How repurposing a drug in a COVID-19 trial could benefit people...
